Frp Advisory Group Plc (FRP)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 128.50 |
|---|---|
| 52-week range | 102.26 – 151.00 |
| Return, 1 month / 3 months | +13.5% / +11.8% |
| Return, 1 year / 3 years | −8.6% / +26.3% |
| Trend | Uptrend |
| RSI (14) | 77 |
| Volatility (1 year) | 23.5% |
| Worst drawdown (1 year) | -29.0% |
| Average daily value traded | 93.19M GBX |
| Dividend yield | 4.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
FRP Advisory Group is a professional services firm based in the United Kingdom that advises companies, lenders and creditors on financial and corporate matters. Its work covers restructuring and insolvency, helping businesses in difficulty, alongside corporate finance, debt advisory and forensic services. Clients include company boards, banks and other stakeholders who need independent advice on turnarounds, formal insolvency processes and transactions. The firm operates through a network of offices across the country and draws on teams of accountants and advisers.
The shares are listed on the London Exchange in UK under the code FRP, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Frp Advisory Group Plc (FRP) trades on the London Exchange in UK. It last closed at GBX 128.50 on 23 October 2026.
Its price-based Market X-Ray is 68 out of 100 (a fair price profile), ranking 704 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 8.6% and over the last three months it rose 11.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 65 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 11.6% | ||
| From 52-week high | -13.2% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 11.8% | ||
| 6-month return | 10.7% | ||
| 12-month return, skipping the last month | -19.5% | ||
| Stability (higher is calmer) | 64 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 23.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.0% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 93.19M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 78 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 4.5% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | +4.0% |
|---|---|
| 1 month | +13.5% |
| 3 months | +11.8% |
| 6 months | +10.7% |
| 1 year | −8.6% |
| 3 years | +26.3% |
| 5 years | +25.8% |
Signals
| 50-day / 200-day average | 117.15 / 115.19 |
|---|---|
| Golden / death cross (60 days) | Golden, 9 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.95 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 19 Nov 2026 | GBP 0.0105 |
| 24 Sep 2026 | GBP 0.0280 |
| 14 May 2026 | GBP 0.0100 |
| 19 Feb 2026 | GBP 0.0100 |
| 20 Nov 2025 | GBP 0.0100 |
| 25 Sep 2025 | GBP 0.0255 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.